• Home
  • Solutions
    • Cell sourcing
      • Cell therapy starting material
      • Immunogenetics & bioinformatics
      • Personalized case management
    • Cell therapy supply chain
      • Collection network development
      • Cell delivery & logistics
      • Personalized case management
      • MatchSource software
    • Clinical research support
      • Clinical trial design
      • Observational research
      • Biorepository & sample access
    • Collection network management
    • Quality & regulatory services
    • Quality System Audit Program
    • MatchSource software
    • Outcomes data reporting
  • About Us
    • History
    • Leadership
    • Upcoming Events
    • Careers
    • Contact
  • Cell Lines Blog
  • Resources
    • Webinars
    • Industry Insights and White Papers
    • Solution Overviews
  • Newsroom
  • Contact Us
  • Twitter
  • LinkedIn
  • Terms of Use
  • Privacy Policy
  • Trademark & Copyright
Be The Match BioTherapies®
MENUMENU
  • Solutions
        • Cell sourcing
          • Cell therapy starting material
          • Immunogenetics & bioinformatics
          • Personalized case management
        • Cell therapy supply chain
          • Collection network development
          • Cell delivery & logistics
          • Personalized case management
          • MatchSource software
        • Clinical research support
          • Clinical trial design
          • Observational research
          • Biorepository & sample access
        • Collection network management
        • Outcomes data reporting
        • Quality & regulatory services
        • Quality System Audit Program
        • MatchSource software
  • About Us
    • History
    • Leadership
    • Upcoming Events
    • Careers
    • Contact
  • Cell Lines Blog
  • Resources
    • Webinars
    • Podcast
    • Industry Insights and White Papers
    • Solution Overviews
  • Newsroom
  • Contact Us
Menu
Cell Lines

In-the-News: March 2018

Be The Match BioTherapies · Industry Updates · April 12, 2018

Subscribe

Get updates from the Cell Lines Blog delivered to your inbox.

March was a banner month for gene therapy, as it marked the commercial debut of the first gene therapy to treat an inherited disease – Spark Therapeutics’ Luxturna. The drug treats people living with inherited retinal diseases caused by the RPE65 gene.

This medical milestone was chronicled around the country as patients looked forward to gaining more vision, independence and a new perspective on life. For uplifting reads, check out this coverage of patients named Jack, Creed and Toby.

In other gene therapy news, researchers at Duke Health are seeking funding to launch a clinical trial of an experimental treatment for Pompe disease. The therapy uses a modified virus to deliver a gene that produces GAA, a critical enzyme missing in people with Pompe disease. Without that enzyme, patients can’t metabolize glycogen so it builds up in the muscles, leading to degradation of the tissue. Untreated, the disease can lead to respiratory problems, heart failure and death. The team at Duke has demonstrated the efficacy of their gene therapy in mice but it has not yet been tested in humans.

Voyager Therapeutics, meanwhile, reported positive data from its small Phase 1b trial for a gene therapy to treat Parkinson’s disease, with some participants showing measurable improvement in motor function. Voyager will use the data to set the parameter for dosing in future clinical trials.

Gene therapy wasn’t the only topic of discussion last month. In Europe, researchers used a stem cell patch to restore some vision in two patients with age-related macular degeneration (AMD). The patch, derived from embryonic stem cells, is being evaluated in a Phase 1 clinical study. This good news, while preliminary, is particularly welcome as the industry continues to grapple with unregulated stem cell clinics and treatments that sometimes produce horrifying consequences for patients. A few years ago three patients with macular degeneration were blinded after undergoing an unregulated stem cell procedure meant to improve their vision.

Finally, we turn to CAR-T news. The first two CAR-T therapies — which involve extracting a patient’s immune cells, engineering them to home in on cancer cells, and then returning them to the patient – were approved last year. Patient Nicole Gularte received a CAR-T treatment as doctors said she was near death from leukemia – and made a strong recovery. She shared her story with the Philadelphia Business Journal in a piece that chronicles the highs and lows of treatment over the years and details her journey from hospice to remission.

Investment is still flowing steadily into CAR-T treatments as JW Therapeutics, a company created by WuXi AppTec and Juno Therapeutics (which is now owned by Celgene), raised a $90 million series A funding round. And in early April, a new CAR-T startup, Allogene Therapeutics, burst on the scene with $300 million in investment from a consortium including Pfizer, Vida Ventures and TPG Capital.

Still curious about how CAR-T works as a precision cancer therapeutic? Check out this video from STAT.

Share this:

  • Facebook
  • Twitter
  • LinkedIn
Tags
CAR-Tgene therapyNews
About the Author
Be The Match BioTherapies

Be The Match BioTherapies

Be The Match BioTherapies partners with organizations pursuing life-saving cellular therapies in every stage of development – from discovery through commercialization. Built on the foundation established over the last 30 years by the National Marrow Donor Program (NMDP)/Be The Match, we have unparalleled experience managing cellular therapies. Our cell therapy supply chain delivery for autologous or allogeneic therapies is enabled by high-touch, personalized case management and a robust, customizable technology platform, MatchSource®. Our experience in cell sourcing and collection allows us to provide cells consented for research, clinical or commercial use. Researchers have access to clinical trial services through our research program CIBMTR. And, we have the infrastructure in place to collect, store and analyze patient samples post-cell or gene therapy treatment at the time points required by regulatory authorities.

More Posts →

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Subscribe

Get updates from the Cell Lines Blog delivered to your inbox.

Close
Be The Match Biotherapies®
  • Terms of Use
  • Privacy Policy
  • Trademark & Copyright
  • Contact

Copyright © 2019 Be The Match BioTherapies. All Rights Reserved.

  • bethematch.org →

    Information and support for patients, donors and supporters of our mission.

  • bethematchclinical.org →

    The latest transplant information for Clinicians, Network, Payers and Bioinformatics.

  • cibmtr.org →

    Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.